TCWM
NBIX icon

Total Clarity Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Total Clarity Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,217
Closed -$303K – 322
2025
Q1 		$303K Hold
2,217
– – 0.1% 193
2024
Q4 		$303K Sell
2,217
-150
-6% -$18.6K 0.1% 194
2024
Q3 		$273K Sell
2,367
-66
-3% -$9.05K 0.09% 203
2024
Q2 		$335K Buy
2,433
+100
+4% +$13.7K 0.12% 175
2024
Q1 		$322K Buy
2,333
+515
+28% +$70.3K 0.11% 195
2023
Q4 		$240K Buy
+1,818
New +$209K 0.1% 204
2020
Q4 		– Sell
-3,210
Closed -$309K – 151
2020
Q3 		$309K Hold
3,210
– – 0.27% 93
2020
Q2 		$392K Hold
3,210
– – 0.36% 80
2020
Q1 		$278K Buy
3,210
+50
+2% +$4.89K 0.43% 75
2019
Q4 		$340K Buy
+3,160
New +$331K 0.26% 83

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Total Clarity Wealth Management's NBIX Position: Q2 2025 in Review

Total Clarity Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 2,217 shares — an estimated $303K sold.

Total Clarity Wealth Management first reported a position in NBIX in Q4 2019 and held it in 10 quarters. The position peaked at $392K in Q2 2020. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Total Clarity Wealth Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Total Clarity Wealth Management sold 2,217 Neurocrine Biosciences shares in Q2 2025, an estimated $303K.
  • Total Clarity Wealth Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 10 quarters.
  • Total Clarity Wealth Management's Neurocrine Biosciences position peaked at $392K in Q2 2020.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Total Clarity Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.